Another line of research [18] has suggested that triptolide can serve as a potent Nrf2 inhibitor, which exhibited selective cytotoxicity to patient-derived IDH1-mutated glioma cells in vitro and in vivo, and can as a valuable therapeutic approach for IDH1-mutated malignancies by targeting the Nrf2-driven glutathione synthesis pathway. The gene discussed is IDH1; the disease is central nervous system cancer.